From: 2D DIGE analysis of maternal plasma for potential biomarkers of Down Syndrome
Spot no. (as on Figure 1) | Accession number (Swiss-Prot) | Abbreviated name | Protein name | Average fold up-regulation (DS/Ctl) | Theoretical mW (Da) | Theoretical pI | Scores for individual spot identifications | Number of sequenced peptides | Peptide positions within the protein | Peptides sequenced (overlap between spots identified per protein) | Coverage (%) (Total number of peptides assigned to protein) | Function |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | P00450 | Ceruloplasmin (Seven spots identified for this protein) | CERU_HUMAN | 3.69 | 122205 | 5.44 | 173, 437, 431, 460, 331, 107, 110 | 8, 17, 16, 15, 12, 7, 7 | 42 - 63 43 - 63 69 - 82 187 - 202 248 - 259 426 - 437 468 - 482 484 - 501 523 - 538 537 - 548 537 - 559 547 - 559 598 - 610 598 - 620 720 - 733 785 - 794 798 - 820 887 - 902 944 - 958 | K.KLISVDTEHSNIYLQNGPDR.I K.LISVDTEHSNIYLQNGPDR.I K.ALYLQYTDETFR.T K.DIASGLIGPLIICK.K K.DNEDFQESNR.M R.EYTDASFTNR.K K.GAYPLSIEPIGVR.F K.NNEGTYYSPNYNPQSR.S K.EVGPTNADPVCLAK.M K.M YYSAVDPTK.D K.M YYSAVDPTKDIFTGLIGPM K.I K.DIFTGLIGPM K.I R.M FTTAPDQVDK.E R.M FTTAPDQVDKEDEDFQESNK.M R.QSEDSTFYLGER.T R.QYTDSTFR.V R.KAEEEHLGILGPQLHADVGDK.V K.DLYSGLIGPLIVCR.R K.VNKDDEEFIESNK.M | 20.6 (19) | Copper-binding glycoprotein, ferroxidase activity, iron transport |
2 | Q14624 | inter-alpha trypsin inhibitor heavy chain H4 | ITIH4_HUMAN | 2.11 | 103357 | 6.51 | 74 | 10 | 98 - 112 152 - 163 214 - 225 299 - 308 428 - 439 500 - 513 633 - 645 657 - 670 815 - 827 831 - 843 | K.AEAQAQYSAAVAK.G R.RLGVYELLLK.V R.FKPTLSQQQK.S K.ILDDLSPR.D K.LALDNGGLAR.R R.GPDVLTATVSGK.L K.IPKPEASFSPR.R R.M NFRPGVLSSR.L K.ETLFSVM PGLK.M K.TGLLLLSDPDK.V | 11.5 (10) | Serine-type endopeptidase inhibitor, acute-phase response, hyaluronan metabolic process |
3 | P0C0L4 | complement C4-A precursor (Two spots identified for this protein) | CO4A_HUMAN | 2.61 | 192771 | 6.66 | 192, 93 | 8, 4 | 756 - 776 916 - 930 979 - 1006 1042 - 1052 1084 - 1100 1291 - 1301 1340 - 1350 1352 - 1366 | R.ALEILQEEDLIDEDDIPVR.S R.GSFEFPVGDAVSK.V R.VTASDPLDTLGSEGALSPGGVASLLR.L K.DHAVDLIQK.G K.VLSLAQEQVGGSPEK.L R.QGSFQGGFR.S K.SHALQLNNR.Q R.GLEEELQFSLGSK.I | 6.5 (8) | Activation of the classical pathway of the complement system |
4 | P01031 | complement C5 precursor | CO5_HUMAN | 1.59 | 188305 | 6.11 | 154 | 6 | 78 - 91 308 - 322 353 - 373 436 - 450 495 - 507 622 - 630 | K.FQNSAILTIQPK.Q K.ELSYYSLEDLNNK.Y K.LNLVATPLFLKPGIPYPIK.V K.TDAPDLPEENQAR.E K.ITHYNYLILSK.G R.VFQFLEK.S | 4.5 (6) | Complement cascade through to formation of membrane attack complex (MAC), inflammatory response |
5 | P02748 | complement component C9 precursor | CO9_HUMAN | 2.38 | 63173 | 5.43 | 196 | 7 | 65 - 77 144 - 155 145 - 155 231 - 243 472 - 484 496 - 509 533 - 544 | R.SIEVFGQFNGK.R R.DRVVEESELAR.T R.VVEESELAR.T K.TSNFNAAISLK.F K.LSPIYNLVPVK.M R.AIEDYINEFSVR.K K.FEGIACEISK.Q | 11.8 (7) | Pore-forming subunit of the MAC that plays a key role in the innate and adaptive immune response |
6 | P01042 | kininogen-1 (Two spots identified for this protein) | KNG1_HUMAN | 1.72 | 71957 | 6.34 | 37, 187 | 6, 9 | 43 - 59 64 - 76 101 - 114 187 - 197 208 - 220 240 - 255 254 - 263 316 - 325 380 - 390 | K.YNSQNQSNNQFVLYR.I K.TVGSDTFYSFK.Y K.AATGECTATVGK.R R.QVVAGLNFR.I K.ENFLFLTPDCK.S R.IASFSQNCDIYPGK.D K.DFVQPPTK.I K.YFIDFVAR.E K.RPPGFSPFR.S | 15.1 (9) | Role in blood coagulation, inhibitor of thiol proteases, inflammatory response, diuresis and natriuresis, smooth muscle contraction, negative regulation of cell adhesion |
7 | P09871 | complement C1s subcomponent precursor (Three spots identified for this protein) | C1S_HUMAN | 4.45 | 76684 | 4.86 | 190, 66 | 8, 5, 6 | 86 - 106 264 - 281 314 - 332 369 - 384 481 - 497 515 - 524 523 - 535 629 - 645 677 - 688 | R.SSNNPHSPIVEEFQVPYNK.L K.SNALDIIFQTDLTGQK.K R.DVVQITCLDGFEVVEGR.V K.VEDPESTLFGSVIR.Y R.EPTM YVGSTSVQTSR.L K.LLEVPEGR.T R.TNFDNDIALVR.L K.GDSGGAFAVQDPNDK.T K.TM QENSTPRED.- | 18.3 (9) | Serine-type endopeptidase involved in activation of classical pathway of the complement system |